Oric Pharmaceuticals, Inc. (ORIC) — SEC Filings
Oric Pharmaceuticals, Inc. (ORIC) — 38 SEC filings. Latest: 8-K (Dec 8, 2025). Includes 12 SC 13G/A, 10 8-K, 6 10-Q.
View Oric Pharmaceuticals, Inc. on SEC EDGAR
Overview
Oric Pharmaceuticals, Inc. (ORIC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: Oric Pharmaceuticals, Inc. filed an 8-K on December 8, 2025, reporting other events and financial statements/exhibits. The filing date for the report is December 6, 2025. The company is incorporated in Delaware and its principal executive offices are located at 240 E. Grand Ave, 2nd Floor, South San
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 3 bullish, 32 neutral, 3 mixed. The dominant filing sentiment for Oric Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Oric Pharmaceuticals, Inc. (ORIC) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 12 SC 13G/A, 6 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of ORIC's 18 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$32.587 million |
| Cash Position | $49.668 million |
| Total Assets | $431.192 million |
Key Executives
- Jacob M. Chacko, M.D.
- Paul Hastings
- David J. Bearss
- Robert J. Cerio
- Abigail P. Johnson
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like ORIC compete on innovation, seeking to develop novel therapies for unmet medical needs. The landscape is dynamic, with ongoing advancements in science and increasing pressure for cost-effective treatments.
Top Tags
institutional-ownership (7) · 10-Q (4) · financials (4) · biotech (4) · passive-investment (4) · Oric Pharmaceuticals (3) · amendment (3) · SC-13G (3) · Biotechnology (2) · Oncology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 20251208 | Date the 8-K was filed with the SEC. |
| Report Date | 20251206 | Earliest event date reported in the filing. |
| Net Loss (Q3 2025) | $32.587 million | Improved from $34.566 million in Q3 2024 |
| Net Loss (YTD Sep 2025) | $98.963 million | Increased from $91.540 million in YTD Sep 2024 |
| Research and Development Expenses (Q3 2025) | $28.773 million | Decreased from $31.202 million in Q3 2024 due to prioritization |
| Workforce Reduction | 20% | Result of strategic pipeline prioritization in Q3 2025 |
| One-time Termination Costs | $1.9 million | Incurred in Q3 2025 due to workforce reduction |
| Cash and Cash Equivalents (Sep 30, 2025) | $49.668 million | Down from $59.406 million at Dec 31, 2024 |
| Total Assets (Sep 30, 2025) | $431.192 million | Increased from $274.142 million at Dec 31, 2024 |
| Net Proceeds from Private Placement (May 2025) | $124.4 million | Strengthened capital position |
| Accumulated Deficit (Sep 30, 2025) | $661.7 million | Reflects significant historical operating losses |
| Common Shares Outstanding (Nov 5, 2025) | 97,389,279 | Increased from 71,021,855 at Dec 31, 2024, indicating dilution |
| Net Loss | $66.376M | Increased from $56.974M in H1 2024, reflecting higher operating expenses. |
| Research and Development Expenses | $55.189M | Increased from $50.900M in H1 2024, indicating continued investment in pipeline. |
| Net Proceeds from Private Placement | $124.4M | Received in May 2025, significantly boosting liquidity. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant stake in Oric Pharmaceuticals for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"Oric Pharmaceuticals' stock price will experience increased stability due to strong institutional backing.","entity":"Oric Pharmaceuticals, Inc.","targetDate":"2024-08-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Oric Pharmaceuticals, Inc. (ORIC)?
Oric Pharmaceuticals, Inc. has 38 recent SEC filings from Jan 2024 to Dec 2025, including 12 SC 13G/A, 10 8-K, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ORIC filings?
Across 38 filings, the sentiment breakdown is: 3 bullish, 32 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Oric Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Oric Pharmaceuticals, Inc. (ORIC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Oric Pharmaceuticals, Inc.?
Key financial highlights from Oric Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ORIC?
The investment thesis for ORIC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Oric Pharmaceuticals, Inc.?
Key executives identified across Oric Pharmaceuticals, Inc.'s filings include Jacob M. Chacko, M.D., Paul Hastings, David J. Bearss, Robert J. Cerio, Abigail P. Johnson.
What are the main risk factors for Oric Pharmaceuticals, Inc. stock?
Of ORIC's 18 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Oric Pharmaceuticals, Inc.?
Recent forward-looking statements from Oric Pharmaceuticals, Inc. include guidance on {"claim":"FMR LLC will maintain a significant stake in Oric Pharmaceuticals for the foreseeable future.","entity":"FMR L and 1 other predictions.